Candesartan Cilexetil vs Sacubitril and Valsartan — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Angiotensin 2 Receptor Blocker

Candesartan Cilexetil

Brand: ATACAND

First FDA approval: 1998-06-04

Angiotensin 2 Receptor Blocker

Sacubitril and Valsartan

Brand: ENTRESTO

First FDA approval: 2015-07-07

Lowest NADACAcquisition cost floor across all NDCs

$0.495Per unit

$0.596Per unit

Average NADACAcross all dosage forms and strengths

$2.14Up to $9.87

$1.49Up to $11.62

Generic manufacturersActive ANDA holders — FDA Orange Book

519 total ANDAs filed

1442 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$61.4MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

759K234K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$81Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

6Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

9Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes5 manufacturers

Yes14 manufacturers